Beta Bionics

Beta Bionics is a United States medical technology company whose work centers on diabetes management. Its public-facing product is the iLet Bionic Pancreas, an insulin-delivery system that the company describes as automatically learning and adapting to the user. The company’s website also highlights compatibility with continuous glucose monitoring sensors, including Dexcom G7 and FreeStyle Libre 3 Plus, and provides information about the iLet app and related support features. The company presents its mission as serving people with differing diabetes needs, experiences, and resources. Its stated focus is not simply technical development: it describes its work as people-centered and oriented toward the wider diabetes community. Beta Bionics also notes that many members of its workforce either live with diabetes or care for someone who does. Beta Bionics was founded in 2015 by Ed Damiano and is headquartered in Irvine, California. It became a publicly traded company on Nasdaq under the ticker BBIO in 2025. Its principal commercial offering is the iLet Bionic Pancreas, supported by associated software, sensor compatibility, and patient-facing services. The company’s present-day website promotes access programs, product updates, and features such as the Bionic Circle and iLet Mirror Display.

Beta Bionics was founded in 2015 by Ed Damiano, with a focus on applying engineering and automation to diabetes management. The company developed the iLet Bionic Pancreas as its central commercial offering. Rather than requiring users to make every insulin-delivery adjustment themselves, the product is presented by the company as an insulin pump that automatically learns and adapts to the user. The iLet platform and its supporting software have been the main focus of Beta Bionics’ public product communications. The company has promoted compatibility with continuous glucose monitoring sensors, including Dexcom G7 and FreeStyle Libre 3 Plus. Its website also communicates app updates and user-oriented functions, such as the iLet Mirror Display, insulin pause controls, and the Bionic Circle feature for inviting friends and family into a user’s support network. Beta Bionics describes its organizational purpose as serving a diverse diabetes community. It acknowledges that people with diabetes have different needs, experiences, and resources, and frames the company as people-focused. The company has also said that many employees either live with diabetes or care for someone who does, connecting its workplace identity with the community it aims to serve. The company is headquartered in Irvine, California. In 2025, Beta Bionics became publicly traded on Nasdaq under the ticker BBIO. Its current public-facing activity includes promoting the iLet system, sensor compatibility, patient access programs, and ongoing app and product features. The available supplied company material emphasizes its products and community-oriented mission; it does not provide a detailed account of every corporate or product-development milestone.

• 2025

  Public listing

• 2015

  Beta Bionics founded

A people-focused diabetes technology company offering automated insulin-delivery solutions designed to adapt to individual users.

• iLet Bionic Pancreas

  The company’s insulin-delivery system, described as automatically learning and adapting to the user.

• iLet app and iLet Mirror Display

  Associated digital features and updates promoted on the company website.

1. 1iLet Bionic Pancreas – the insulin pump that automatically learns and adapts to you.betabionics.com
2. 2Bringing innovative type 1 diabetes management solutions to the manybetabionics.com
3. 3At Beta Bionics, people are at the heart of everything we dobetabionics.com
4. 4Meet the ‘who’ behind the ‘what’ we do at Beta Bionicsbetabionics.com
5. 5BETA BIONICS, INC.wikidata.org